ACLARIS
PharmaACLARIS is a pharmaceutical company focused on Dermatology, Immunology. Key products include ESKATA.
ACLARIS at a Glance
- Strong track record with 87% execution quality across 33 trials
- Fast trial execution (9 months median completion)
ACLARIS's Key Drugs
ACLARIS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ACLARIS's Recent FDA Approvals
New NDA/BLA approvals for ACLARIS over the last two years — novel drugs only, excluding generics and label supplements.
ACLARIS's Therapeutic Areas
ACLARIS's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ACLARIS's Top Competitors
ACLARIS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ACLARIS Pipeline Snapshot
ACLARIS has 14 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 14 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/6 completed
- • Speed: 9 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2017-12-14
- Latest
- 2019-02-07
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges